Review articleBupropion for major depressive disorder: Pharmacokinetic and formulation considerations
References (66)
- et al.
A systematic review of the associations between dose regimens and medication compliance
Clin Ther
(2001) - et al.
A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline
Clin Ther
(1999) - et al.
Continuation phase treatment with bupropion SR decreases the risk for relapse of depression
Biol Psychiatry
(2002) - et al.
Safety profile of sustained-release bupropion in depression: Results of three clinical trials
Clin Ther
(1999) - et al.
Steady-state pharmacokinetics of bupropion SR in juvenile patients
J Am Acad Child Adolesc Psychiatry
(2005) - et al.
In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography
Biol Psychiatry
(2003) - et al.
Medical causes of seizures
Lancet
(1998) - et al.
The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R)
Jama
(2003) Diagnostic and Statistical Manual of Mental Disorders: DSM-IVTR
Practice guideline for the treatment of patients with major depressive disorder (revision)
Am J Psychiatry
(2000)
A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor
Prim Care Companion J Clin Psychiatry
(2004)
Wellbutrin (bupropion) tablets
Wellbutrin SR (bupropion)
Wellbutrin XL (bupropion)
A prospective safety surveillance study for bupropion sustained-release in the treatment of depression
J Clin Psychiatry
(1998)
Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation
Nicotine Tob Res
(2001)
15 Years of clinical experience with bupropion HCl: From bupropion to bupropion SR to bupropion XL
Prim Care Companion J Clin Psychiatry
(2005)
Prevalence of sexual dysfunction among newer antidepressants
J Clin Psychiatry
(2002)
A fixed-dose efficacy study of bupropion and placebo in depressed patients
J Clin Psychiatry
(1990)
A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients
J Clin Psychiatry
(1983)
A comparative study of bupropion and amitriptyline in depressed outpatients
J Clin Psychiatry
(1983)
Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder
J Clin Psychopharmacol
(1986)
Comparison of bupropion and trazodone for the treatment of major depression
J Clin Psychopharmacol
(1994)
A double-blind trial of bupropion versus desipramine for bipolar depression
J Clin Psychiatry
(1994)
A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults
Am J Psychiatry
(2001)
A comparison of sustained-release bupropion and placebo for smoking cessation
N Engl J Med
(1997)
Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms
Obes Res
(2002)
Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects
Eur J Clin Pharmacol
(1981)
Metabolism and kinetics of bupropion
J Clin Psychiatry
(1983)
Bupropion occupancy of the dopamine transporter is low during clinical treatment
Psychopharmacology (Berl)
(2002)
The effect of bupropion on the activity of dopamine transporter in depression-preliminary results
Eur Neuropsychopharmacol
(2003)
Cited by (195)
Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression
2022, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :The risks associated with an acute rise in blood pressure with esketamine may be further exacerbated by the addition of bupropion or a prodopaminergic stimulant (Daly et al., 2019). Other adverse effects associated with bupropion include, but are not limited to, headache, weight loss, dry mouth, dizziness, and difficulty sleeping (Jefferson et al., 2005). A few of these potential side effects appear to be dose-dependent, and, if bupropion, or another dopaminergic agent, were to be combined with esketamine, a lower dose of the former may be all that is required to achieve the augmenting benefit of the adjunctive therapy.
The Timing of Clinical Effects of Bupropion Misuse Via Insufflation Reported to a Regional Poison Center
2022, Journal of Emergency MedicineMagnetic nanoparticles and their application in bioanalysis
2022, Fundamentals and Industrial Applications of Magnetic NanoparticlesBasic Principles of Drug Discovery and Development
2021, Basic Principles of Drug Discovery and Development
Copyright © 2005 Published by Elsevier Inc.